Butyrylglycine
Butyrylglycine is a glycine conjugate of butyric acid, a short-chain fatty acid, and is an endogenous metabolite found in human biological fluids. As part of the broader metabolome, its levels can reflect various physiological states and metabolic processes within the body.
Biological Basis
Butyrylglycine is typically formed through the conjugation of butyrate with glycine, a process that can occur as part of detoxification pathways or as a consequence of microbial metabolism in the gut. Its presence in the body is indicative of metabolic activity involving short-chain fatty acids, which play roles in energy metabolism and gut health. The study of such metabolites, known as metabolomics, aims to comprehensively measure endogenous metabolites in body fluids to provide a functional readout of physiological states. [1]
Clinical Relevance
Variations in metabolite profiles, including compounds like butyrylglycine, are increasingly recognized for their clinical significance. Genome-wide association studies (GWAS) have demonstrated that genetic variants can associate with changes in the homeostasis of key lipids, carbohydrates, or amino acids, providing insights into disease mechanisms. [1] For example, genetic factors have been linked to conditions such as type 2 diabetes, which is characterized by altered glucose metabolism [2], [3] and to metabolic syndrome pathways. [4] Understanding how genetic variations influence metabolites like butyrylglycine can contribute to identifying individuals at risk for various metabolic disorders and elucidating underlying biochemical pathways.
Social Importance
The investigation of metabolites and their genetic determinants holds significant social importance for advancing personalized medicine and public health. By linking genetic polymorphisms to specific metabolite profiles, researchers can gain a more detailed understanding of disease-causing mechanisms, which often have small effect sizes when only associating genotypes with clinical outcomes. [1] This approach can lead to improved risk prediction, earlier disease detection, and the development of targeted interventions for conditions influenced by metabolic dysregulation. The comprehensive measurement of metabolites offers a functional readout of the physiological state, enabling a deeper insight into the interplay between genetics, environment, and health. [1]
Methodological and Statistical Considerations
Research into butyrylglycine is subject to several methodological and statistical constraints that can impact the interpretation of findings. Many studies operate with moderate sample sizes, which can limit the statistical power to detect genetic effects of modest size, potentially leading to false negative findings. [5] Conversely, the extensive multiple testing inherent in genome-wide association studies (GWAS) increases the risk of false positive associations, particularly for findings that have not yet been independently replicated across different cohorts. [6]
Further limitations arise from the scope of genetic variation surveyed; reliance on a subset of available SNPs, such as those included on specific gene chips or from particular HapMap builds, means that some causal variants or genes influencing butyrylglycine levels may be missed due to incomplete genomic coverage or suboptimal imputation quality. [7] Additionally, choices in analytical models, such as performing only sex-pooled analyses, may obscure genetic associations that are specific to either males or females, and a singular focus on multivariable models might overlook important bivariate relationships between genetic variants and butyrylglycine. [7]
Phenotype Characterization and Generalizability
The accurate characterization and measurement of butyrylglycine levels, and related phenotypes, present significant challenges that can limit the precision and applicability of research findings. When studies use surrogate markers or indirect indicators, such as cystatin C for kidney function or TSH for thyroid function, without comprehensive assessments of the underlying physiological states, it can introduce ambiguities in the interpretation of genetic associations. [6] Furthermore, the practice of averaging phenotypic traits over extended periods, sometimes spanning decades and involving different measurement equipment, can lead to misclassification and potentially mask age-dependent genetic effects, as it assumes consistent genetic and environmental influences across a wide age range. [8]
A major limitation for the generalizability of findings is the lack of ethnic diversity in many study cohorts, which are often predominantly composed of individuals of European descent. [6] This demographic homogeneity makes it uncertain how the genetic associations identified for butyrylglycine would apply to other ancestral groups. Moreover, the exclusion of individuals on specific medications, such as lipid-lowering therapies, while necessary for some study designs, can further restrict the applicability of findings to the broader population who may be undergoing such treatments. [9]
Unaccounted Influences and Mechanistic Gaps
Current research often faces limitations in fully accounting for the complex interplay of genetic and environmental factors that influence butyrylglycine levels, leaving significant gaps in mechanistic understanding. Many studies do not explicitly investigate gene-environment interactions, which are critical because genetic variants can influence phenotypes in a context-specific manner, with environmental factors potentially modulating their effects. [8] This omission means that important biological interactions, such as those between specific genes and dietary intake, remain unexplored, leading to an incomplete understanding of the full scope of genetic contributions to butyrylglycine metabolism. [8]
While GWAS are effective at identifying statistical associations between genetic variants and butyrylglycine levels, they frequently cannot directly infer the underlying disease-causing mechanisms or differentiate between multiple causal variants within the same gene region. [1] Consequently, the identified genetic variants may merely be in linkage disequilibrium with unknown causal variants, complicating the precise pinpointing of true functional loci and the elucidation of the specific biochemical pathways involved in butyrylglycine regulation. [3]
Variants
The ACADS gene, encoding short-chain acyl-CoA dehydrogenase, plays a crucial role in mitochondrial fatty acid beta-oxidation, a fundamental process for energy production within cells, particularly during periods of fasting or high energy demand. This enzyme is responsible for the first step in the breakdown of short-chain fatty acids, converting butyryl-CoA into crotonyl-CoA. Variants in the ACADS gene, such as rs2014355 and rs34673751, can affect the efficiency of this enzyme, leading to a reduced capacity to metabolize short-chain fatty acids. [1] When ACADS activity is impaired, there can be an accumulation of its substrate, butyryl-CoA, which is then shunted towards alternative metabolic pathways, leading to the formation and excretion of butyrylglycine. Elevated levels of butyrylglycine are a characteristic biochemical marker associated with short-chain acyl-CoA dehydrogenase deficiency (SCADD), a condition that can manifest with symptoms ranging from asymptomatic to severe metabolic crises, impacting energy homeostasis and potentially leading to hypoglycemia and muscle weakness. [10]
The CPS1 gene encodes carbamoyl phosphate synthetase I, a critical enzyme situated in the mitochondria of liver and intestinal cells, initiating the urea cycle. The urea cycle is the primary pathway for detoxifying ammonia, a toxic byproduct of protein and amino acid metabolism, by converting it into urea for excretion. The variant rs1047891 within the CPS1 gene can influence the activity or expression of this enzyme, potentially affecting the efficiency of ammonia detoxification. [7] Impaired CPS1 function can lead to hyperammonemia, a serious metabolic condition that, if left untreated, can result in neurological damage and other severe health complications. While CPS1 does not directly metabolize butyrylglycine, its central role in nitrogen metabolism and overall mitochondrial health means that variations in its function can impact the broader metabolic landscape, potentially influencing pathways that interact with fatty acid oxidation or amino acid conjugation, thereby affecting overall metabolic stability. [1]
Key Variants
| RS ID | Gene | Related Traits |
|---|---|---|
| rs2014355 rs34673751 |
ACADS | metabolite measurement serum metabolite level protein measurement ethylmalonate measurement methylsuccinate measurement |
| rs1047891 | CPS1 | platelet count erythrocyte volume homocysteine measurement chronic kidney disease, serum creatinine amount circulating fibrinogen levels |
Causes
The provided research does not contain specific information regarding the causes of butyrylglycine.
Regulation of Glucose and Lipid Metabolism
Glucose metabolism is a fundamental cellular process, with genes like HK1 (hexokinase 1) playing a role in the initial phosphorylation of glucose, and variations influencing glycated hemoglobin levels in non-diabetic populations. [2] The regulation of blood glucose is further influenced by genes such as G6PC2 and ABCB11, with polymorphisms in these regions impacting fasting plasma glucose levels. [2] Disturbances in these pathways can affect beta-cell function and contribute to conditions like type 2 diabetes and insulin resistance. [2]
Lipid metabolism is intricately linked with glucose homeostasis and overall metabolic health. Genetic variations in genes like MLXIPL are associated with plasma triglyceride levels, highlighting their role in lipid processing. [11] Similarly, other loci, including those near LEPR, HNF1A, IL6R, and GCKR, are implicated in metabolic syndrome pathways and can influence plasma C-reactive protein, a marker of inflammation, as well as triglycerides and insulinemia. [4] These genetic factors collectively modulate the balance of lipids, such as low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides, which are critical for energy storage and cellular structure. [9]
Uric Acid Homeostasis and Transport
The maintenance of uric acid levels, or urate homeostasis, is a complex process involving both production and excretion, with significant genetic influences. The gene SLC2A9, also known as GLUT9, has been identified as a key urate transporter, and variations within this gene profoundly impact serum urate concentration and its excretion. [12] SLC2A9 influences uric acid levels with pronounced sex-specific effects and is associated with conditions like gout and hyperuricemia. [12] Its role extends to the transport of various organic anions, indicating a broader involvement in metabolite clearance. [12]
The biological activity of GLUT9 is primarily observed in the liver and kidney, organs central to uric acid metabolism and excretion. [13] In the liver, where a substantial amount of uric acid is synthesized, GLUT9 can modulate glucose uptake, potentially affecting downstream metabolic pathways like the pentose phosphate shunt and phosphoribosyl pyrophosphate synthesis, which in turn influence hepatic uric acid production. [13] In the kidney, GLUT9 is expressed in distal nephron segments and plays a role in renal uric acid regulation and clearance, with specific splice variants like GLUT9ΔN exclusively found in kidney proximal tubules, the primary site of uric acid handling. [14] Disruptions in these processes, as seen in hereditary fructosemia or glucose-6-phosphatase deficiency, can lead to hyperuricemia and other metabolic disturbances. [14]
Systemic Metabolic Interconnections and Organ Function
Metabolic processes are highly interconnected, with disruptions in one area often leading to systemic consequences affecting multiple organs. For instance, plasma levels of liver enzymes can serve as indicators of metabolic health, and variations influencing these levels are associated with conditions like type 2 diabetes and the metabolic syndrome. [15] Inflammation, often measured by markers such as C-reactive protein, is a critical component of metabolic dysfunction and is influenced by genetic loci related to metabolic-syndrome pathways. [4] The interplay between these factors underscores the systemic nature of metabolic disorders, where hepatic, renal, and endocrine functions are tightly regulated.
The heart and vascular system are also significantly impacted by metabolic health. Genetic factors related to echocardiographic dimensions and endothelial function highlight the cardiovascular consequences of metabolic imbalances. [8] Conditions like cardiac hypertrophy and diastolic dysfunction are noted in the context of metabolic stress. [8] Furthermore, imbalances in uric acid, cholesterol, and various hormones can contribute to cardiovascular disease incidence, emphasizing the intricate web of metabolic and organ-level interactions that maintain overall physiological homeostasis. [6]
Genetic and Molecular Regulatory Networks
Genetic variations play a crucial role in shaping individual metabolic profiles and disease susceptibility. Genome-wide association studies have identified numerous loci that influence diverse metabolic traits, from serum uric acid and triglyceride levels to glycated hemoglobin and liver enzyme activity. [12] These genetic determinants often involve genes encoding critical proteins, enzymes, and receptors that participate in signaling pathways and metabolic processes, such as the glucokinase regulator GCKR involved in glucose and triglyceride metabolism, or the leptin receptor LEPR associated with metabolic syndrome pathways. [4]
Beyond the coding sequences, regulatory elements and gene expression patterns are essential for precise control of metabolic functions. Transcription factors like HNF-1 can synergistically trans-activate gene promoters, as seen with the human C-reactive protein promoter, demonstrating complex regulatory networks. [4] Other molecular players, such as carboxypeptidase N, function as pleiotropic regulators of inflammation, while components like erlin-1, erlin-2, and Sam50 are involved in membrane insertion and protein sorting, indicating the intricate cellular machinery that supports metabolic health and responds to homeostatic disruptions. [15] These molecular mechanisms collectively dictate how cells respond to metabolic cues and maintain physiological balance.
References
[1] Gieger C. et al. Genetics meets metabolomics: a genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008.
[2] Pare, G., et al. "Novel association of HK1 with glycated hemoglobin in a non-diabetic population: a genome-wide evaluation of 14,618 participants in the Women's Genome Health Study." PLoS Genetics, vol. 4, no. 12, 2008, p. e1000312. PMID: 19096518.
[3] Sabatti, Chiara, et al. "Genome-wide association analysis of metabolic traits in a birth cohort from a founder population." Nature Genetics, vol. 40, no. 12, 2008, pp. 1391–1398.
[4] Ridker, P. M., et al. "Loci related to metabolic-syndrome pathways including LEPR,HNF1A, IL6R, and GCKR associate with plasma C-reactive protein: the Women's Genome Health Study." American Journal of Human Genetics, vol. 82, no. 5, 2008, pp. 1185-92. PMID: 18439548.
[5] Benjamin, Emelia J., et al. "Genome-wide association with select biomarker traits in the Framingham Heart Study." BMC Medical Genetics, vol. 8, 2007.
[6] Hwang, S. J., et al. "A genome-wide association for kidney function and endocrine-related traits in the NHLBI's Framingham Heart Study." BMC Medical Genetics, vol. 8, 2007, p. 69. PMID: 17903292.
[7] Yang Q. et al. Genome-wide association and linkage analyses of hemostatic factors and hematological phenotypes in the Framingham Heart Study. BMC Med Genet. 2007.
[8] Vasan, R. S., et al. "Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study." BMC Medical Genetics, vol. 8, 2007, p. 65. PMID: 17903301.
[9] Kathiresan, S., et al. "Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans." Nature Genetics, vol. 40, no. 2, 2008, pp. 189-97. PMID: 18193044.
[10] Wallace C. et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet. 2008.
[11] Kooner, J. S., et al. "Genome-wide scan identifies variation in MLXIPL associated with plasma triglycerides." Nature Genetics, vol. 40, no. 2, 2008, pp. 189-94. PMID: 18193046.
[12] Vitart, V., et al. "SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout." Nature Genetics, vol. 40, no. 4, 2008, pp. 432-6. PMID: 18327257.
[13] Li, S., et al. "The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts." PLoS Genetics, vol. 3, no. 11, 2007, p. e194. PMID: 17997608.
[14] McArdle, P. F., et al. "Association of a common nonsynonymous variant in GLUT9 with serum uric acid levels in old order amish." Arthritis & Rheumatism, vol. 58, no. 9, 2008, pp. 2894-901. PMID: 18759275.
[15] Yuan, X., et al. "Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes." American Journal of Human Genetics, vol. 83, no. 4, 2008, pp. 520-8. PMID: 18940312.